Antithrombotic use and bleeding risk in patients with atrial fibrillation: findings from a multipayer analysis

Area of Science:

• Cardiology
• Pharmacology
• Health Services Research

Background:

• Atrial fibrillation (AF) is a common arrhythmia associated with increased risk of stroke and bleeding.
• Antithrombotic therapy is crucial for stroke prevention in AF patients, but its utilization varies.
• Real-world data on antithrombotic use in AF patients is essential for understanding adherence to guidelines.

Purpose of the Study:

• To estimate stroke risk, bleeding risk, and antithrombotic treatment patterns in patients with atrial fibrillation (AF).
• To analyze administrative claims data from diverse insurance sources (Medicaid, Medicare, commercial).
• To compare real-world antithrombotic use against established stroke prevention guidelines.

Main Methods:

• Analysis of administrative claims data from six databases.
• Inclusion of 115,906 patients aged ≥18 years with a new or existing AF diagnosis.
• Assessment of 1-year outcomes including stroke risk (CHADS2/CHA2DS2-VASc scores) and bleeding risk (ATRIA scores).

Main Results:

• A significant proportion of high-stroke-risk (CHADS2 ≥2) and low-bleeding-risk (ATRIA 0-3) AF patients did not receive antithrombotic therapy (42-82%).
• The study identified substantial variation in treatment patterns across different patient subgroups and data sources.
• Anticoagulant use was evaluated as a key outcome measure.

Conclusions:

• Real-world thromboprophylaxis for high-risk AF patients significantly deviates from current medical guidelines.
• There is a critical need to improve adherence to evidence-based stroke prevention strategies in AF management.
• Findings highlight opportunities for clinical decision support and quality improvement initiatives.